Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by garygpon May 30, 2022 2:08pm
96 Views
Post# 34717516

RE:RE:RE:RE:RE:Expecting tangible news soon

RE:RE:RE:RE:RE:Expecting tangible news soonI understand that doing a consolidation later would be to our advantage if the share price were allowed to somehow rise, and a rising sp is highly unlikely under new guidance.  The FSG are the new masters and the two clowns, Goldstein and Williams are the new messengers.  This collective group are all about 'them" and could give two sh*ts about us.

We as shareholders are like characters in an old World War Two movie; hands and feet bound, eyes covered, mouth gagged, on our knees with a beady-eyed little character standing over us waiting to lopp-off our collective heads.  All I'm saying is we know the end result and it won't be pretty so lets just get the dirty deed done.  Our real future is in the hands of Neil Cashman and nobody else. 

And as far as shareholder engagement or knowledge goes, look no further than the results of the AGM and the vote.  Management were given an overwhelming mandate to do as they bloody well want.  Waiting to consolidate until after P1 results could help shareholders so for that reason I see it taking place sooner than later.  To do it now favours management, not us, so why wait.
<< Previous
Bullboard Posts
Next >>